SG Americas Securities’s Freeline Therapeutics Holdings FRLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-3,444
Closed -$45K – 3656
2022
Q2
$45K Sell
3,444
-513
-13% -$6.6K ﹤0.01% 3278
2022
Q1
$66K Buy
3,957
+319
+9% +$5.92K ﹤0.01% 2819
2021
Q4
$108K Buy
3,638
+479
+15% +$19.6K ﹤0.01% 3051
2021
Q3
$163K Buy
+3,159
New +$225K ﹤0.01% 3367

Other funds holding FRLN

SG Americas Securities's FRLN Position: Q3 2022 in Review

SG Americas Securities sold out of Freeline Therapeutics Holdings (FRLN) in Q3 2022, closing a stake of 3,444 shares — an estimated $45K sold.

SG Americas Securities first reported a position in FRLN in Q3 2021 and held it in 4 quarters. The position peaked at $163K in Q3 2021. 14 funds tracked by Wall St. Rank hold FRLN as of Q3 2022.

  • SG Americas Securities reported no remaining Freeline Therapeutics Holdings position as of Q3 2022 after selling out during the quarter.
  • SG Americas Securities sold 3,444 Freeline Therapeutics Holdings shares in Q3 2022, an estimated $45K.
  • SG Americas Securities first reported a position in Freeline Therapeutics Holdings in Q3 2021 and held it in 4 quarters.
  • SG Americas Securities's Freeline Therapeutics Holdings position peaked at $163K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q3 2022.

Based on SG Americas Securities's 13F filing for Q3 2022, filed 31 Oct 2022.